Drug Companies Are Flocking to Facebook for Eyeballs, Not Conversation

18 March 2010

More and more pharmaceutical companies are launching Facebook pages that promote their products.

Read the full story

Posted in:  Traditional Strategies     Comments

Twittering FDA - An Analysis of FDA’s Twittering Activity

18 March 2010

Read the full story

Posted in:  Regulatory     Comments

Good Suppliers - And The Other Guys

18 March 2010

Is it just me, or is the fine chemicals supply business getting even more out of hand than usual?

Read the full story

Posted in:  In the Pipeline     Comments

Dietary Supplements, Charted

17 March 2010

I'm a complete sucker for dense but well-presented information, and this one isn't bad at all: here's a chart of nutritional supplements by the strength of the evidence for them in human trials. I haven't cross-checked the data, but the authors appear to have done some homework in PubMed, at least, and haven't included any non-human or in vitro data. The interactive version at the link is particularly fun to mess around with.

Read the full story

Posted in:  In the Pipeline     Comments

Theft at Eli Lilly

17 March 2010

$75 million dollars worth of antipsychotics - that's a lot of pills, and I'm not surprised to see that the thieves used a tractor-trailer to haul everything off.

Read the full story

Posted in:  In the Pipeline     Comments

Make Your Compound Go Away

18 March 2010

I'm not sure that the term will catch on, but this new paper proposes "antedrug" to describe a compound that's deliberately designed to be cleaved quickly to something inactive. I see where they're coming from - reverse of "prodrug" - but in spoken English it's too close to "anti-drug".

Read the full story

Posted in:  In the Pipeline     Comments

Johnson & Johnson Urges FDA to Be As Flexible As FTC in Its Regulation of Social Media, But…

18 March 2010

In comments to the FDA, Johnson & Johnson (JNJ) stated "Flexibility in regulatory approach is crucial in the evolving digital world." The comment was part of an 8-page document submitted to Docket No.

Read the full story

Posted in:  Traditional Strategies, Web Marketing     Comments

More Blogroll

17 March 2010

Here's another addition: A New Merck, Reviewed , which is someone's attempt to dig through everything about the new Merck/Schering-Plough hybrid. I'm not sure that all the info is reliable, of course, and whoever writes this has a strange way with italics> /i> , but it's worth a look.

Read the full story

Posted in:  In the Pipeline     Comments

Novartis Proposes Use of Unique FDA-Approved Short URLs & Hashtags to Overcome Space Limitation Issues of Social Media

17 March 2010

Novartis submitted 6 pages of comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools ( find it here ). Novartis made many interesting proposals on how FDA should regulate the use of social media by drug companies, but I'd like to focus on one of particular interest to me: special FDA-sanctioned short URLs and hashtags that make it easy for consumers to find product-safety information and for the FDA to review social media communications for compliance.

Read the full story

Posted in:  Web Marketing     Comments

Should Sanofi-Aventis Submit an Adverse Event Report Based on "Disgruntled Patient’s" Comments to VOICES FB Page?

17 March 2010

Sanofi-Aventis (S-A) submitted 14 pages of comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools ( find it here )

Read the full story

Posted in:  Traditional Strategies, Web Marketing     Comments